ArticleEngineering in life sciences2025
High Cell Density Perfusion Process of Quail Cells Producing Oncolytic rVSV-NDV.
Article in Engineering in life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- High Cell Density Cultivation of HEK293 Cells Using a 2L Membrane-Stirred Bioreactor.Biotechnology and bioengineering · 2026Article
- Developing an oncolytic Newcastle disease virus production process with EB66 cells.Applied microbiology and biotechnology · 2026Article
- Stability of the two enveloped viruses NDV LaSota and YF-ZIKprM/E to support process development.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses as agents for the treatment of various types of cancer have demonstrated their potential in many clinical studies over the past decades. In particular, rVSV-NDV (a recombinant vesicular stomatitis virus [VSV] construct with fusogenic Newcastle disease virus glycoproteins) shows promising preclinical results. This is due to its safety profile, immunostimulatory effects, and efficacy based on strong syncytia formation. Since virotherapy requires a high input of infectious viruses, efficient production processes are needed. Good manufacturing practice (GMP)-compliant CCX.E10 cells have been previously reported as a high-titer-producing rVSV-NDV candidate in batch mode. Here, semi-perfusion was used to test quail-originated CCX.E10 cells for rVSV-NDV production at high cell densities and in different cell culture media. The best condition was transferred to a full perfusion process in a 3 L bioreactor using a tangential follow depth filtration (TFDF) device for cell retention. The integrated depth filter with a pore size of 2-5 µm allowed 99.9% cell retention at viable cell concentrations (VCCs) of up to 20.6 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.